Back to news

Ascendis Pharma Falls as Investors Reassess Novo Rights Reversion and Pipeline Execution Risk

Investivoq PriceTracker

Ascendis Pharma (ASND) is down 6.1% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver is continued investor concern after Ascendis said it will take back full rights to its metabolic and cardiovascular TransCon programs following the end of its Novo Nordisk collaboration. While the company also authorized a $400 million share repurchase, the market appears more focused on the added development burden, longer timelines, and execution risk tied to funding and advancing those assets on its own.

Details:

  • Ascendis said all rights to TransCon technology-based products in metabolic and cardiovascular diseases, including once-monthly TransCon semaglutide, will revert back to the company.
  • The company said it plans to initiate multiple programs in those areas, including obesity and type 2 diabetes, which implies a broader and potentially more capital-intensive development path.
  • Ascendis separately announced a planned share repurchase program of up to $400 million, a shareholder-friendly step that may not have been enough to offset concerns about strategy and execution.
  • An analyst downgrade followed the rights reversion announcement, suggesting some on Wall Street see the partnership shift as increasing risk even if the long-term asset opportunity remains intact.

    • Sources:

    Ascendis Pharma, Benzinga, MarketBeat

    Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

    $ASND Insider Trading Activity

    ASND Insider Trades

    $ASND insiders have traded $ASND stock on the open market 11 times in the past 6 months. Of those trades, 9 have been purchases and 2 have been sales.

    Here’s a breakdown of recent trading of $ASND stock by insiders over the last 6 months:

    • MADS BODENHOFF (SVP & PAO) sold 3,000 shares for an estimated $810,570
    • JEAN JACQUES BIENAIME has made 7 purchases buying 2,900 shares for an estimated $699,336 and 0 sales.
    • SCOTT THOMAS SMITH (EVP & Chief Financial Officer) has made 2 purchases buying 350 shares for an estimated $77,730 and 0 sales.
    • LARS HOLTUG sold 236 shares for an estimated $62,334

    To track insider transactions, check out Investivoq's insider trading dashboard. You can access data on insider stock transactions through the Investivoq API insider transaction endpoint.

    Investivoq Alerts
    Receive ASND Data Alerts
    Get market-moving data, filings, and signals for ASND in real time.
    Sign Up

    $ASND Hedge Fund Activity

    We have seen 178 institutional investors add shares of $ASND stock to their portfolio, and 184 decrease their positions in their most recent quarter.

    Here are some of the largest recent moves:

    • T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 5,674,622 shares (+525.3%) to their portfolio in Q2 2026, for an estimated $1,513,535,179
    • BLACKROCK, INC. added 1,550,779 shares (+234.6%) to their portfolio in Q2 2026, for an estimated $413,623,774
    • ARTISAN PARTNERS LIMITED PARTNERSHIP removed 596,164 shares (-18.5%) from their portfolio in Q2 2026, for an estimated $159,008,862
    • NOMURA ASSET MANAGEMENT INTERNATIONAL INC. removed 556,427 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $148,410,209
    • CITADEL ADVISORS LLC removed 519,516 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $118,828,894
    • PRICE T ROWE ASSOCIATES INC /MD/ removed 407,816 shares (-26.6%) from their portfolio in Q2 2026, for an estimated $108,772,683
    • JPMORGAN CHASE & CO added 367,781 shares (+inf%) to their portfolio in Q2 2026, for an estimated $98,094,548

    To track hedge funds' stock portfolios, check out Investivoq's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Investivoq API 13F endpoint.

    $ASND Price Targets

    Multiple analysts have issued price targets for $ASND recently. We have seen 7 analysts offer price targets for $ASND in the last 6 months, with a median target of $326.0.

    Here are some recent targets:

    • Luca Issi from RBC Capital set a target price of $280.0 on 07/07/2026
    • Eric Joseph from Citigroup set a target price of $355.0 on 05/19/2026
    • Josh Schimmer from Evercore ISI Group set a target price of $329.0 on 05/15/2026
    • Eliana Merle from Barclays set a target price of $345.0 on 05/11/2026
    • Derek Archila from Wells Fargo set a target price of $326.0 on 05/08/2026
    • Tazeen Ahmad from B of A Securities set a target price of $292.0 on 04/16/2026
    • Yun Zhong from Wedbush set a target price of $273.0 on 04/09/2026

    This article is not financial advice. See Investivoq's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.